GGrantIndex
← Leaderboards

Anthony W Tolcher

University Of Texas Hlth Sci Ctr San Ant

Google Scholar ↗PubMed ↗ORCID ↗
$2,350,887
Attributed
$2,350,887
Total exposure
11
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $550.9K · FY2005–07
$1M$750K$500K$250K$0
'05
'06
'07

Funding mix

By agency

NIH$2,350,887 · 11

By mechanism

U01$1,493,540 · 1
M01$857,347 · 10

Top collaborators

No co-investigators on record.

Most similar at University Of Texas Hlth Sci Ctr San Ant

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research”

Research focus

Clinical ResearchHuman SubjectDrug Screening /EvaluationHuman Therapy EvaluationClinical Trial Phase INeoplasm /Cancer ChemotherapyPharmacokineticsDosageDrug Adverse EffectAntineoplasticsDrug Administration Rate /DurationOral AdministrationIntravenous AdministrationMetastasisNeoplasm /Cancer Classification /StagingPaclitaxelChild (0-11)Alkylating AgentsAntifungal AgentsGene TherapyGenetic TranscriptionBenzimidazolesAnalogAntiviral Agents

Grant awards (29)

PH I STUDY OF EGFR AND HER2 BLOCKADE W/ OSI-774, TRASTUZUMAB AND PACLITAXEL$12,053
M01 · FY2007 · RR · contact PI
Phase I Clinical Trials of Anti-Cancer Agents$497,588
U01 · FY2006 · CA · contact PI
PH I STUDY OF EGFR AND HER2 BLOCKADE W/ OSI-774, TRASTUZUMAB AND PACLITAXEL$23,191
M01 · FY2006 · RR · contact PI
Phase I Clinical Trials of Anti-Cancer Agents$503,913
U01 · FY2005 · CA
PH I STUDY OF EGFR AND HER2 BLOCKADE W OSI-774, TRASTUZUMAB AND PACLITAXEL$45,529
M01 · FY2005 · RR
PH II PK AND BIOLOGIC CORRELATIVE STUDY OF OSI-774 IN PTS W/ ADV RENAL CELL CARC$1,441
M01 · FY2005 · RR
Phase I Clinical Trials of Anti-Cancer Agents$492,039
U01 · FY2004 · CA
Phase I/II Study of Oblimersen Sodium with Leucovorin$53,129
M01 · FY2004 · RR
Ph II Pharmakokinetic/Biologic Study of OSI-774 in RCC$1,084
M01 · FY2004 · RR
PHASE I STUDY OF CYCLIC ORAL ADMINISTRATION OF SCH61365 (21 OF 28 DAYS)$234,837
M01 · FY2002 · RR
PHASE I STUDY OF CYCLIC ORAL ADMINISTRATION OF SCH61365 (21 OF 28 DAYS)$234,837
M01 · FY2002 · RR
PHARMACOKINETICS/SAFETY OF INGN 201 IN ADVANCED TUMORS$0
M01 · FY2002 · RR
PHARMACOKINETICS OF FB 642 IN PATIENTS WITH ADVANCED TUM$0
M01 · FY2002 · RR
PHARMACOKINETICS OF FB 642 IN PATIENTS WITH ADVANCED TUM$0
M01 · FY2002 · RR
PHARMACOKINETICS/SAFETY OF INGN 201 IN ADVANCED TUMORS$0
M01 · FY2002 · RR
TRIAL OF RPR 116258A--1 HR IV INFUSION IN SOLID TUMORS$0
M01 · FY2002 · RR
TRIAL OF RPR 116258A--1 HR IV INFUSION IN SOLID TUMORS$0
M01 · FY2002 · RR
PHARMACOKINETICS OF SR45023A 7 DAY ADMINISTRATION CYCLE$0
M01 · FY2002 · RR
PHARMACOKINETICS OF SR45023A 7 DAY ADMINISTRATION CYCLE$0
M01 · FY2002 · RR
PHASE I STUDY OF CYCLIC ORAL ADMINISTRATION OF SCH61365 (21 OF 28 DAYS)$234,837
M01 · FY2001 · RR
PHARMACOKINETICS OF SR45023A 7 DAY ADMINISTRATION CYCLE$0
M01 · FY2001 · RR
TRIAL OF RPR 116258A--1 HR IV INFUSION IN SOLID TUMORS$0
M01 · FY2001 · RR
PHARMACOKINETICS/SAFETY OF INGN 201 IN ADVANCED TUMORS$0
M01 · FY2001 · RR
PHARMACOKINETICS OF FB 642 IN PATIENTS WITH ADVANCED TUM$0
M01 · FY2001 · RR
PHASE I STUDY OF CYCLIC ORAL ADMINISTRATION OF SCH61365 (21 OF 28 DAYS)$16,409
M01 · FY2000 · RR
PHARMACOKINETICS/SAFETY OF INGN 201 IN ADVANCED TUMORS$0
M01 · FY2000 · RR
PHARMACOKINETICS OF SR45023A 7 DAY ADMINISTRATION CYCLE$0
M01 · FY2000 · RR
TRIAL OF RPR 116258A--1 HR IV INFUSION IN SOLID TUMORS$0
M01 · FY2000 · RR
PHARMACOKINETICS OF FB 642 IN PATIENTS WITH ADVANCED TUM$0
M01 · FY2000 · RR